HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide].

Abstract
Short-course chemotherapy of six-month duration with an initial combination of three drugs (isoniazid [H], rifampin [R] and pyrazinamide [Z]) is recommended as the treatment of choice in tuberculosis today. Use of fixed-combination tablet (Rifater) prevents prescription errors by physicians and selective intake by noncompliant patients. It should therefore assist in the prevention of emergence of drug resistance. In a controlled study at a chest hospital in Switzerland involving 261 patients with culture proven tuberculosis, the following two regimens were compared: 1) Six-month therapy (n = 128) with daily Rifater for two months, followed by H and R for four months. 2) Nine-month therapy (n = 133) with H and R daily for nine months, supplemented by ethambutol for the first two months. The two patient groups were comparable except for initial drug resistance (16% vs 8%, p < 0.05). Overall resistance to H was 10%. Five patients had initial resistance to two or more drugs. 227 patients were re-examined 1-8, and on average 4 years after therapy: four patients relapsed after 12, 20, 36 and 90 months. Two patients with initial drug resistance to H later developed resistance to R; both of these, as well as a third relapse patient, were cured with subsequent multi-drug therapy. Despite two and a half years of chemotherapy and repeated surgery, the fourth patient with initial resistance to H and R could not be cured. All relapse patients with initial drug resistance were randomized into the six-month therapy group.(ABSTRACT TRUNCATED AT 250 WORDS)
AuthorsO Brändli, D Dreher, D Morger
JournalSchweizerische medizinische Wochenschrift (Schweiz Med Wochenschr) Vol. 123 Issue 25 Pg. 1300-6 (Jun 26 1993) ISSN: 0036-7672 [Print] Switzerland
Vernacular TitleErgebnisse der Tuberkulose-Kurzzeittherapie mit Isoniazid, Rifampicin und Pyrazinamid.
PMID8341998 (Publication Type: Case Reports, Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)
Chemical References
  • Antitubercular Agents
  • Drug Combinations
  • isoniazid, pyrazinamide, rifampin drug combination
  • Pyrazinamide
  • Isoniazid
  • Rifampin
Topics
  • Adult
  • Antitubercular Agents (administration & dosage)
  • Drug Combinations
  • Drug Resistance, Microbial
  • Female
  • Humans
  • Isoniazid (administration & dosage)
  • Male
  • Middle Aged
  • Patient Compliance
  • Pyrazinamide (administration & dosage)
  • Rifampin (administration & dosage)
  • Time Factors
  • Tuberculosis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: